Drugs / Quadrivalent Recombinant Influenza Vaccine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06118151 | Apr 2022 → Feb 2023 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05144945 | Dec 2021 → Sep 2022 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03969641 | Sep 2019 → Sep 2021 | — | Duke University | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1/2 | NCT06361875 Comparator | Apr 2024 → Jun 2025 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 1/2 | NCT05650554 Comparator | Dec 2022 → Apr 2024 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 1/2 | NCT05553301 Comparator | Oct 2022 → Jan 2024 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Press releases naming this drug 2 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quadrivalent Recombinant Influenza Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06361875 ↗ |
| Known as | RIV4 | “Quadrivalent Recombinant Influenza Vaccine (RIV4)” NCT05144945 ↗ |
| Modality | Vaccine | “The first recombinant inactivated influenza vaccine” NCT03969641 ↗ |
| Route | Intramuscular | “single dose intramuscular RIV4” PMID 40752250 ↗ Aug 2025 |